Clinical Trials

We Help your Immunity to Help you Live a Healthier Life.

CanovaTM Served millions of patients since 1950s’. The researches suggests that CanovaTM medication act in the enhancement of the immune response by:

  • Macrophages activation; which modifies immune system to enhance its’ function.
  • Absence of toxicity and mutagenicity.
  • Relative increase of total number of subtypes of leukocytes and lymphocytes (CD4, CD8, NK and B), reverting – partly the effect of some pathologies.
  • Increases the production of nitric oxide.
  • Decreases the production of TNF-alpha thus reversing the weakness and wasting of the body felt due to severe chronic illness.
  • Increases phagocytosis index and the endosomal-lysosomal system index in macrophages, increasing these cells efficiency in natural defence mechanism.
  • Decreases the inflammatory response while accelerating the healing process.
  • Decreases the tumour volume and produces fibrosis (collagen type I) around the tumour mass.
  • Restoration of several haematological parameters during and after chemotherapy thus improving the tolerability and duration of treatments against cancer and overall Quality of Life.
  • Decreases opportunistic diseases / infections.

Clinical Trials - Quality Of Life

  • Prof. Dr. Dorly de F. Buchi, Patients recovery with HIV/AIDS in Botswana/Africa, with the use of CanovaTM, summary of the master’s dissertation to PG program in Cellular and Molecular Biology , sector of biological sciences, Federal University of Parana, Curitiba 2006.

Clinical Trials - Hiv/Aids

  • Unison Medicare & Research Centre Pvt. Ltd., Clinical study to evaluate efficacy of Immune-Modulator CanovaTM in HIV/AIDS Patients.
  • Prof. Dr. Dorly de Freitas Buchi, HIV/AIDS+patients treated with CanovaTM: Prospective observational study in laboratory, clinical and quality of life indexes, summary of the master’s dissertation to PG program in Cellular and Molecular Biology , sector of biological sciences, Federal University of Parana, Curitiba 2005.
  • Maria das Gracas da Mota Silveira Sasaki, Randomized placebo-controlled clinical trial to appraise the effectiveness and safety of immunomodulatory CanovaTM in the therapeutics of patients who have HIV/AIDS on anti-retroviral use, Federal University of Parana, 2001.

Cinical Trial – Cancer, N=1120 For 12 Months

Decrease of Collateral effects such as :

  • Nausea and Vomits
  • Regulating Digestion
  • Recovers Weight
  • Reduce Weakness

CANOVATM Treatment reduces the appearance of tumor cells resistance to the Chemotherapy agents.

  • Maintains the regularity of Oncologic Treatment
  • Maintains the Normality of Plateletmetry and Leukometry.
  • CANOVATM Treatment reduces the need for hemotransfusion.

Cinical Trial - Cancer

Cinical Trial - Cancer
Cinical Trial - Cancer
  • 1. Dr. Castanheira et al., "To rescue therapeutic forms that can guarantee better longr life with quality", Evaluation of CanovaTM use in patients with Cancer.
  • 2. Cabral et al., Clinical study work for evaluation of Immunemodulatoe CanovaTM in the therapeutics of Oncology patient considered OTP.

Clinical Trials - Asthma

Clinical Trials - Asthma
Clinical Trials - Asthma

(1) Dr. Paulo de Tarso Castanheira, "Physician, Director of the Ambulatory of the Medical Clinic at the City Hospital from Riachinho/MG, Trial from July to November 2006

Canova’s Clinical Trials

JOIN OUR COMMUNITY